欧洲 · 通讯社与实时数据 · ANP

Paradigm Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Trial for SD-101 (Zorblesia™) in Epidermolysis Bullosa

来源：ANP · 荷兰 9 小时前

SD-101 (Zorblesia™) is the First Topical Therapy Being Developed to Treat Wounds and Lesions Across the Entire Skin Surface in Patients with Three Major Subtype ...

在 ANP 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (persportaal.anp.nl)

Paradigm Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Trial for SD-101 (Zorblesia™) in Epidermolysis Bullosa

推荐阅读

Repeated Ukrainian attacks could lead to a major regional tragedy — Rosatom CEO

Türkiye's Central Bank cuts policy rate to 36% after 5 consecutive holds

Nigeria bourse CEO says Dangote refinery IPO to widen investor base

Sainsbury's raises profit outlook but sales growth slowdown hits shares

Cette vidéo montre une manifestation propalestinienne en 2025 et non la mobilisation lycéenne de 2026

Barclays to slash 5,000 jobs in AI-powered cost-cutting drive

Paradigm Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Trial for SD-101 (Zorblesia™) in Epidermolysis Bullosa

分享

推荐阅读

Repeated Ukrainian attacks could lead to a major regional tragedy — Rosatom CEO

Türkiye's Central Bank cuts policy rate to 36% after 5 consecutive holds

Nigeria bourse CEO says Dangote refinery IPO to widen investor base

Sainsbury's raises profit outlook but sales growth slowdown hits shares

Cette vidéo montre une manifestation propalestinienne en 2025 et non la mobilisation lycéenne de 2026

Barclays to slash 5,000 jobs in AI-powered cost-cutting drive